Purinoceptor P2Y12: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Daniel Mietchen
(+subpages)
 
Line 1: Line 1:
{{subpages}}
In [[biochemistry]] and [[signal transduction]], '''purinoceptor P2Y<sub>12</sub>''' is a [[G-protein-coupled receptor]] (a [[cell surface receptor]]). It is a subtype of [[purinergic P2 receptor]] that is a "receptor for [[Adenosine diphosphate|ADP]] and [[Adenosine triphosphate|ATP]] coupled to G-proteins that inhibit the adenylyl cyclase [[second messenger system]]; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of [[thromboembolism]]s and other clotting disorders."<ref>{{MeSH}}</ref>
In [[biochemistry]] and [[signal transduction]], '''purinoceptor P2Y<sub>12</sub>''' is a [[G-protein-coupled receptor]] (a [[cell surface receptor]]). It is a subtype of [[purinergic P2 receptor]] that is a "receptor for [[Adenosine diphosphate|ADP]] and [[Adenosine triphosphate|ATP]] coupled to G-proteins that inhibit the adenylyl cyclase [[second messenger system]]; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of [[thromboembolism]]s and other clotting disorders."<ref>{{MeSH}}</ref>



Latest revision as of 10:48, 14 December 2009

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In biochemistry and signal transduction, purinoceptor P2Y12 is a G-protein-coupled receptor (a cell surface receptor). It is a subtype of purinergic P2 receptor that is a "receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of thromboembolisms and other clotting disorders."[1]

Clinical role

Blockers of P2Y12 include the thienopyridines clopidogrel and prasugrel which are irreversible and require at least 1 hour or longer to inhibit platelets. Cangrelor is a reversible blocker that acts quicker.

References